We are live on
!
Find out more
RM
RP Management Portfolio holdings
AUM
$139M
1-Year Est. Return
37.98%
This Fund
S&P 500
This Quarter
Est. Return
-24.7%
1 Year Est. Return
-37.98%
3 Year Est. Return
+207.8%
5 Year Est. Return
+1,098.05%
10 Year Est. Return
–
AUM
$179M
AUM Growth
-$1.32M
(-0.74%)
Cap. Flow
+$59.2M
Cap. Flow
% of AUM
33.09%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cytokinetics
CYTK
|
+$59.2M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biohaven
BHVN
$2.43B
| $102M | 57% |
2,936,507
| – | – |
|
|
2
Cytokinetics
CYTK
$10.8B
| $53.1M | 29.71% |
+980,392
| New | +$59.2M |
|
3
BioCryst Pharmaceuticals
BCRX
$2.52B
| $23.8M | 13.29% |
3,846,154
| – | – |
|
|
VIRX
4
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $2K | ﹤0.01% |
3,700
| – | – |
|
Similar funds
PC
LA
TP
SC
MADFP
RM
NC
GWA
RP Management's Q2 2024 Portfolio in Review
As of Q2 2024, RP Management held 4 positions worth $179M, down 0.74% from $180M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
RP Management deployed $59.2M of net new capital in Q2 2024, opening 1 new position. Its largest new stake was Cytokinetics: 980,392 shares worth $53.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- RP Management's largest Q2 2024 buy was Cytokinetics: 980,392 shares worth $53.1M.
- RP Management's ten largest holdings make up 100% of its $179M portfolio in Q2 2024.
- RP Management opened 1 new position and closed 0 in Q2 2024.
- RP Management's portfolio value fell 0.74% quarter-over-quarter to $179M.
Based on RP Management's 13F filing for Q2 2024, filed 13 Aug 2024.